Clinical Trial Update: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4, 6-month randomized open-label trial comparing Fingolimod (FTY720) 0.5 mg/day with a comparator in relapsing forms of multiple sclerosis; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Forms of Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2013-12-05